• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table H-2Strength of evidence for the comparative efficacy of leukotriene modifiers (LMs)

Number of studies (# of subjects)DesignQualityConsistencyDirectnessResult and magnitude of effectOther modifying factorsaOverall Strength of the evidence
Overall total: LM compared with LM
1 (40)RCT (12 weeks)FairNADirectNo differenceNoneLow
Montelukast compared with Zafirlukast
1 (40)RCT (12 weeks)FairNADirectNo differenceNoneLow
Montelukast compared with Zileuton
We did not identify any systematic reviews or head-to-head trials
Zafirlukast compared with Zileuton
We did not identify any systematic reviews or head-to-head trials

Abbreviations: LM= Leukotriene Modifiers; MA= meta-analysis; RCT= randomized controlled trial; SR= systematic review.

a

Imprecise or sparse data; a strong or very strong association; high risk of reporting bias; dose response gradient; effect of plausible residual confounding.

Imprecise or sparse data; a strong or very strong association; high risk of reporting bias; dose response gradient; effect of plausible residual confounding.

From: Appendix H, Strength of evidence

Cover of Drug Class Review: Controller Medications for Asthma
Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet].
Jonas DE, Wines RCM, DelMonte M, et al.
Portland (OR): Oregon Health & Science University; 2011 Apr.
Copyright © 2011 by Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.